Fig. 2

Clinical outcomes in C57BL/6 infected mice untreated or treated with SGE (10 or 30 µg). A Clinical scores were assessed daily over the 23-day treatment period. B Overall clinical scores; C The percentage of weight loss; D Survival rates measurements. Differences in daily scores, daily loss percentage weight, and overall score analysis were analyzed using one-way ANOVA. Significant variations were indicated as follows: asterisks (*) indicate comparisons between treated animals 10 µg and 30 µg (* p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001); Hashtag (#) indicate comparisons between untreated and treated animals (SGE 30 µg), (# p ≤ 0.05, ## p ≤ 0.01, ### p ≤ 0.001); Ampersand (&) indicate comparisons between untreated and treated animals (SGE 10 µg) (p ≤ 0.05, && indicates p ≤ 0.01, &&&). Small intestine length in C57BL/6 mice infected or not with T. gondii and treated or not with SGE (10 µg or 30 µg) during chronic or acute phases. E Represents the measured length of the small intestine. Data were analyzed using 2-way ANOVA followed by Tukey’s multiple comparison post-test. F Illustrates the percentage of shortening Asterisks indicated statistical significance, * p ≤ 0.05 and ** p ≤ 0.01 (n = 10 mice per group)